When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.
We examined sponsorship of published cost-effectiveness analyses of statin use for cardiovascular (CV) prevention, and determined whether the funding source is associated with study conclusions.We searched PubMed/MEDLINE (up to June 2011) to identify cost-effectiveness analyses of statin use for CV...
Main Authors: | Ferrán Catalá-López, Gabriel Sanfélix-Gimeno, Manuel Ridao, Salvador Peiró |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3704635?pdf=render |
Similar Items
-
Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies
by: Catalá-López Ferrán, et al.
Published: (2012-10-01) -
Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis.
by: Ferrán Catalá-López, et al.
Published: (2012-01-01) -
PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS
by: S. Y. Martsevich, et al.
Published: (2016-01-01) -
PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS
by: S. Y. Martsevich, et al.
Published: (2016-01-01) -
New paradigm of treatment with statins in cardiovascular prevention
by: Carlo Vigorito, et al.
Published: (2016-01-01)